Tolecizumab (Actemra, RoActemra)
Immunotherapy · Approved since 2010
Description
Tolecizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor and is being explored in combination with chemoimmunotherapy for proficient mismatch repair (pMMR) and microsatellite stable (MSS) locally advanced colon adenocarcinoma. This agent works by blocking IL-6 signaling, which plays a role in inflammation and immune suppression in the tumor microenvironment. The drug is primarily approved for autoimmune conditions like rheumatoid arthritis but is now being tested in colorectal cancer to enhance the effectiveness of existing chemoimmunotherapy regimens.
Mechanism of Action
Tolecizumab binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 from activating downstream signaling pathways including JAK/STAT3. By blocking IL-6 signaling, the drug aims to reduce tumor-promoting inflammation and potentially improve immune cell infiltration and function within the tumor microenvironment of MSS colorectal cancers, which are typically resistant to standard immunotherapy approaches.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Actemra, RoActemra |
| Category | Immunotherapy |
 Status | Off-label |
| Administration | IV, Subcutaneous |
| Year Approved | 2010 |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.